RecruitingNCT01347047
HIBA-Institutional Registry of Amyloidosis
Institutional Registry of Amyloidosis (Hospital Italiano de Buenos Aires)
Sponsor
Hospital Italiano de Buenos Aires
Enrollment
500 participants
Start Date
Apr 1, 2011
Study Type
OBSERVATIONAL
Conditions
Summary
1. Creating a population-based registry system Amyloidosis prospective epidemiological survey * risk factors * diagnosis * prognosis * treatment * monitoring * survival 2. Describe the occurrence of amyloidosis in the population of HIBA, Hospital Italiano de Buenos Aires. 3. Describe the characteristics of clinical presentation, evolution and predisposing factors of amyloidosis.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Cases of amyloidosis are captured by electronic medical records whenever the physician register amyloidosis as a patient diagnosis, and/or there is amyloidosis in a biopsy specimen and/or requests for the following studies of an adult patient: plasma kappa and lambda light-chain concentrations, the kappa: lambda ratio, transthoracic Doppler echocardiography, or cardiovascular magnetic resonance examination or pyrophosphate scintigraphy From the possible cases included in the IRA, a prospective review of the electronics health records was performed to confirm the presence of amyloidosis
- Patients over 18 years:
- Confirmed amyloidosis: Proof of deposit of amyloid pathology by tissue biopsy in abdominal fat, bone marrow, rectum or organ involved (eg, kidney, liver, sural nerve)
- Clinically compatible case of Amyloidosis :
Exclusion Criteria1
- Refusal to participate in the study or the informed consent process by the patient or legal representative or refusal to consent to participate in the study in the case of minors.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01347047
Related Trials
NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
NCT062517781 location
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
NCT069748771 location
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
NCT057584931 location
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT0656389598 locations
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT0708164618 locations